Bioventus Inc's (NASDAQ:BVS) Q4 FY21 sales increased 32.3% Y/Y (5.1% organically) to $130.4 million, almost in line with the consensus of $130.3 million.
- Sales increased primarily due to recent acquisitions. International net sales increased 71% Y/Y on an actual and constant currency basis.
- The adjusted gross profit margin compressed to 76.3%, down from 79.7% a year ago.
- The adjusted operating margin was 17.1%, compared to 17.7% a year ago.
- Adjusted net income increased 39% Y/Y to $17.6 million. EPS of $0.26 surpassed the consensus of $0.18.
- Adjusted EBITDA reached $28.5 million, compared to $28.2 million in Q4 FY20.
- Guidance: Bioventus expects FY22 sales of $545 million - $565 million, representing Y/Y growth of 26% - 31%, compared to the consensus of $558.52 million.
- The Company expects adjusted EBITDA of $94 million - $107 million.
- Price Action: BVS shares are up 0.69 at $13.96 during the market session on the last check Thursday.
